Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Non-Current Assets: 2017-2024

Historic Non-Current Assets for Aclaris Therapeutics (ACRS) over the last 8 years, with Dec 2024 value amounting to $94.4 million.

  • Aclaris Therapeutics' Non-Current Assets rose 49.69% to $74.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $74.9 million, marking a year-over-year increase of 49.69%. This contributed to the annual value of $94.4 million for FY2024, which is 37.68% up from last year.
  • As of FY2024, Aclaris Therapeutics' Non-Current Assets stood at $94.4 million, which was up 37.68% from $68.5 million recorded in FY2023.
  • In the past 5 years, Aclaris Therapeutics' Non-Current Assets registered a high of $94.4 million during FY2024, and its lowest value of $13.3 million during FY2020.
  • For the 3-year period, Aclaris Therapeutics' Non-Current Assets averaged around $62.0 million, with its median value being $68.5 million (2023).
  • Per our database at Business Quant, Aclaris Therapeutics' Non-Current Assets surged by 247.45% in 2021 and then tumbled by 50.09% in 2022.
  • Over the past 5 years, Aclaris Therapeutics' Non-Current Assets (Yearly) stood at $13.3 million in 2020, then spiked by 247.45% to $46.2 million in 2021, then slumped by 50.09% to $23.0 million in 2022, then surged by 197.44% to $68.5 million in 2023, then skyrocketed by 37.68% to $94.4 million in 2024.